| payload |
{"created_at":"2026-04-07T03:18:43.308 {"created_at":"2026-04-07T03:18:43.308311+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:d6b903bad4551c9b","evidence_event_ids":["evt_22d6b9f1df1a"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001438533-26-000028.txt","as_of":"2026-04-07T03:18:43.308311+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001438533-26-000028.txt","company":"Travere Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001438533-26-000028.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_26e9859774c6a9b1","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001438533-26-000028.txt","content_type":"text/plain","enriched_at":"2026-04-07T08:20:03.215442+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"Document","final_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001438533-26-000028.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001438533-26-000028.txt","source_event_id":"evt_22d6b9f1df1a","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEFA14A","fp":"373b8e716635e548","kind":"sec_filing","published_at":"20260406","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":1.0,"dates_mentioned":["2026-04-06","2026-05-19"],"entities":[{"asset_class":"equity","name":"Travere Therapeutics, Inc.","relevance":"high","symbol":"TVTX","type":"company"}],"event_type":"listing","information_gaps":["No specific changes from prior filings are detailed."],"key_facts":["Filing date: April 6, 2026","Annual meeting scheduled for May 19, 2026","Proposals include election of directors and approval of equity incentive plan."],"numeric_claims":[],"primary_claim":"Travere Therapeutics, Inc. filed a DEFA14A on April 6, 2026.","relevance_score":0.8,"sentiment":"neutral","source_quality":"high","summary":"Travere Therapeutics, Inc. filed a DEFA14A proxy statement for its upcoming annual meeting, detailing proposals for director elections and other corporate matters.","topics":["proxy statement","annual meeting","corporate governance"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEFA14A \u00b7 Travere Therapeutics, Inc. \u00b7 Filed 20260406","ticker":"TVTX","tickers":["TVTX"],"title":"TVTX filed DEFA14A","url":"https://www.sec.gov/Archives/edgar/data/1438533/0001438533-26-000028.txt"}}... |